Transient Inhibition of the JAK/STAT Pathway Prevents B-ALL Development in Genetically Predisposed Mice

Researchers showed in Pax5+/– mice that transient, early-life administration of clinically relevant doses of ruxolitinib, a JAK1/2 inhibitor, significantly mitigated the risk of B cell acute lymphoblastic leukemia following exposure to infection.